159 related articles for article (PubMed ID: 25528551)
1. A survey of treatment approaches of malignant ascites in Germany and Austria.
Jehn CF; Küpferling S; Oskay-Özcelik G; Lüftner D
Support Care Cancer; 2015 Jul; 23(7):2073-8. PubMed ID: 25528551
[TBL] [Abstract][Full Text] [Related]
2. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.
Wimberger P; Gilet H; Gonschior AK; Heiss MM; Moehler M; Oskay-Oezcelik G; Al-Batran SE; Schmalfeldt B; Schmittel A; Schulze E; Parsons SL
Ann Oncol; 2012 Aug; 23(8):1979-1985. PubMed ID: 22734013
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer and ascites: A questionnaire on current management in the United kingdom.
Macdonald R; Kirwan J; Roberts S; Gray D; Allsopp L; Green J
J Palliat Med; 2006 Dec; 9(6):1264-70. PubMed ID: 17187534
[TBL] [Abstract][Full Text] [Related]
4. Malignant ascites symptom cluster in patients referred for paracentesis.
Husain A; Bezjak A; Easson A
Ann Surg Oncol; 2010 Feb; 17(2):461-9. PubMed ID: 19866240
[TBL] [Abstract][Full Text] [Related]
5. Malignant Ascites: Validation of a Novel Ascites Symptom Mini-Scale for Use in Patients With Ovarian Cancer.
Eitan R; Raban O; Tsoref D; Jakobson-Setton A; Sabah G; Salman L; Yeoshua E; Ben-Haroush A
Int J Gynecol Cancer; 2018 Jul; 28(6):1162-1166. PubMed ID: 29664840
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Procedures for Malignant Ascites in a Palliative Care Outpatient Clinic.
Korpi S; Salminen VV; Piili RP; Paunu N; Luukkaala T; Lehto JT
J Palliat Med; 2018 Jun; 21(6):836-841. PubMed ID: 29489450
[TBL] [Abstract][Full Text] [Related]
7. The role of "closed abdomen" hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.
Orgiano L; Pani F; Astara G; Madeddu C; Marini S; Manca A; Mantovani G
Support Care Cancer; 2016 Oct; 24(10):4293-9. PubMed ID: 27169699
[TBL] [Abstract][Full Text] [Related]
8. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites.
Easson AM; Bezjak A; Ross S; Wright JG
Ann Surg Oncol; 2007 Aug; 14(8):2348-57. PubMed ID: 17505860
[TBL] [Abstract][Full Text] [Related]
9. Palliation of malignant ascites.
Hodge C; Badgwell BD
J Surg Oncol; 2019 Jul; 120(1):67-73. PubMed ID: 30903617
[TBL] [Abstract][Full Text] [Related]
10. Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.
Kurbacher CM; Horn O; Kurbacher JA; Herz S; Kurbacher AT; Hildenbrand R; Bollmann R
Oncologist; 2015 Nov; 20(11):1333-41. PubMed ID: 26417039
[TBL] [Abstract][Full Text] [Related]
11. Patients' perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life-a study of the North-Eastern-German Society of Gynecological Oncology.
Armbrust R; Neeb C; Thuss-Patience P; Lüftner D; Pietzner K; Riess H; Oskay-Öczelik G; Richter R; Keller M; Sehouli J
Arch Gynecol Obstet; 2019 May; 299(5):1385-1389. PubMed ID: 30834969
[TBL] [Abstract][Full Text] [Related]
12. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
Pilanc KN; Ordu Ç; Akpnar H; Balc C; Başsülü N; Köksal Üİ; Elbüken F; Okutur K; Bülbül G; Sağlam S; Demir G
Am J Ther; 2016; 23(4):e1078-81. PubMed ID: 24732906
[TBL] [Abstract][Full Text] [Related]
13. A survey of current practice in the management of recurrent malignant ascites among oncologists and palliative-care physicians in the UK.
Newman G; Pudney D
Clin Oncol (R Coll Radiol); 2006 Mar; 18(2):154. PubMed ID: 16523820
[No Abstract] [Full Text] [Related]
14. [Ascites paracentesis].
Er F; Erdmann E; Pfister R
Dtsch Med Wochenschr; 2007 May; 132(21):1177-9. PubMed ID: 17506014
[No Abstract] [Full Text] [Related]
15. Acceptance, Prevalence and Indications for Robot-Assisted Laparoscopy - Results of a Survey Among Urologists in Germany, Austria and Switzerland.
Imkamp F; Herrmann TR; Tolkach Y; Dziuba S; Stolzenburg JU; Rassweiler J; Sulser T; Zimmermann U; Merseburger AS; Kuczyk MA; Burchardt M
Urol Int; 2015; 95(3):336-45. PubMed ID: 26160360
[TBL] [Abstract][Full Text] [Related]
16. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
[TBL] [Abstract][Full Text] [Related]
17. Pattern and prognostic factors in patients with malignant ascites: a retrospective study.
Ayantunde AA; Parsons SL
Ann Oncol; 2007 May; 18(5):945-9. PubMed ID: 17298959
[TBL] [Abstract][Full Text] [Related]
18. Repeat Large-Volume Paracentesis Versus Tunneled Peritoneal Catheter Placement for Malignant Ascites: A Cost-Minimization Study.
Bohn KA; Ray CE
AJR Am J Roentgenol; 2015 Nov; 205(5):1126-34. PubMed ID: 26496562
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
Krawczyk M; Zimmermann S; Vidacek D; Lammert F
Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
[TBL] [Abstract][Full Text] [Related]
20. Management of symptomatic ascites and post-operative lymphocysts with an easy-to-use, patient-controlled, vascular catheter.
Stukan M; Leśniewski-Kmak K; Wróblewska M; Dudziak M
Gynecol Oncol; 2015 Mar; 136(3):466-71. PubMed ID: 25434633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
